AIM ImmunoTech Inc (AIM) has released an update to notify the public and investors about a regulation fd disclosure.
AIM has provided a presentation with additional data on its Pancreatic Cancer Early Access Program for the first quarter of 2024, available on its website. The provided information is not considered officially filed for regulatory purposes but may be referenced in future filings if explicitly stated.
For further insights into AIM stock, check out TipRanks’ Stock Analysis page.
